Bharat Biotech's Covaxin found to be safe, induced immune response in Phase-1

Bharat Biotech's Covaxin was granted restricted emegency use approval in 'clinical trial mode' on January 2.

Bharat Biotech's coronavirus vaccine Covaxin has been found to be well-tolerated and produced an immune response, says the Phase-1 interim data published by the company in the peer-reviewed British medical journal Lancet.

The findings come at a time amid reports that some healthcare workers, including doctors, were not turning up to take the indigenously developed jab, which was given the emergency approval under the "trial mode", over safety concerns.